CSF2 and congenital rubella syndrome: Alternate treatments to tocilizumab for reducing CRS and neuroinflammation are being investigated in preclinical studies; these include the neutralization of GM-CSF with lenzilumab (an anti-GM-CSF monoclonal antibody) (199) and GM-CSF−/− CAR T-cells (203).